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model; (HR 80-100 bpm paced and unpaced, MAP 70-100 mmHg, Cuff displace-
ment 14 cc per beat). The counterpulsation effect was optimized in 1:2 mode and
measurements made in 1:1 mode (Fig 1). The measured motor power was
2.7-3.9W. There was no significant temperature gradient measured at either the
pump or internal coil versus surrounding tissues.
Conclusions: A fully implanted counterpulsation system is technically feasible, with low
power usage and no requirement for an implanted battery. Furthermore, the system can be
coupled with brady-tachy pacemaker technology, allowing for a novel, synergistic
electrical–mechanical cardiac assist system.
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Background: Refractory angina pectoris despite medical therapy in patients who are not
amenable for revascularization procedures is a relatively common clinical problem.The
quality of life of these no-option patients with so-called therapy-refractory angina pectoris
is poor as these patients need to change their life style according to their level of pain and
anxiety. A potential solution to alleviate the problem of reversible subendocardial
ischemia is to redistribute intramyocardial blood flow from the less ischemic subepicardial
myocardium towards the under-perfused and ischemic subendocardial myocardium.This
can be achieved by implanting a Reducer in the coronary sinus (CS). The hourglass-
shaped stent-like device creates over time a narrowing thereby increasing the venous
pressure and thus allowing intramyocardial flow reversal relieving the symptoms of pain
due to ischemia.
Methods: The COSIRA (Coronary Sinus Reducer for Treatment of Refractory
Angina) is a prospective, multicenter, randomized, double-blind, sham-controlled
clinical trial of the safety and effectiveness of the CS Reducer. The trial is
ongoing, and more than 80 patients have been enrolled in Europe and Canada. It
consists of baseline assessments, implantation of the Reducer in the study group,
and assessments of both study and sham-control groups at hospital discharge, 30
days, 3 months and 6 months.
Results: The primary endpoint of this trial is a decrease in two or more CCS grades from
baseline to six-month post-procedural evaluation in Reducer and control groups. A
parallel CS Reducer registry is ongoing, in which patients with refractory angina are
treated with CS Reducer implantation on a compassionate use basis.
Conclusions: The 6 months safety results of the COSIRA trial as well as the safety and
efficacy results of the Reducer registry will be presented at TCT 2012.
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Background: Despite advances in cardiovascular medicine, acute decompensated heart
failure and post-cardiotomy shock is associated with alarmingly high mortality rates. Until
recently, temporary mechanical support has included the intra-aortic balloon pump
(IABP) and extracorporeal membrane oxygenation (ECMO). The Impella 5.0 device is a
minimally invasive microaxial pump, designed to provide superior clinical support for
these failing patients in a cost-effective manner.
Methods: This retrospective study compares the economic outcomes of patients
receiving circulatory support with either ECMO or the Impella LP5.0, and builds on our
previously published clinical study on these patients. Hospital resource data was collected
for both study arms, to include blood product costs, perfusion costs, ICU costs, and length
of stay (LOS) for 29 Impella and 31 ECMO patients.
Results: In a well-matched clinical sample of Impella and ECMO patients, total
mean costs to the hospital were reduced by 12% for the initial index stay of
Impella patients. This reduction was driven by a significant 61% reduction in
blood product costs (p0.001), confirming the minimally invasive design of the
Impella cardiac assist device. Related, there was a 100% reduction in perfusion
costs, as Impella patients do not require perfusion assistance. Additionally, ICU
costs were reduced in the Impella arm by 25%, driven primarily by 4.8 fewer ICU
days of stay for Impella patients.
Conclusions: For patients requiring emergent hemodynamic support, the Impella cardiac
assist device appears to offer a less invasive alternative that not only improves outcomes
but also reduces costs over ECMO therapy. These findings have significant operational
implications for providers, both in the single-payer Canadian system, as well as in the U.S.
healthcare system as providers embrace recent health reforms.
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Background: The national rates of in-hospital mortality in patients undergoing pericar-
diocentesis in the United States are not known.
Methods: The Nationwide Inpatient Sample (NIS) database was used to identify patients
who underwent pericardiocentesis from 2005 to 2009. We used risk-adjusted logistic
regression to analyze the predictors of in-hospital mortality.
Results: A total of 49,850 patients underwent pericardiocentesis during the five-year
study period. The in-hospital mortality was noted to be 15.5%. The following factors were
identified as significant independent predictors of in-hospital death: shock (OR 4.65; 95%
CI 3.99-5.41), renal failure (OR 1.24; 95% CI 1.06-1.45), peripheral vascular disease (OR
1.32; 95% CI 1.04-1.67), neurologic disorders (OR 1.74; 95% CI 1.38-2.20), metastatic
cancer (OR 1.74; 95% CI 1.45-2.09), coagulopathy (OR 1.91; 95% CI 1.60-2.26),
electrolyte abnormalities (OR 1.55; 95% CI 1.38-1.74) and liver disease (OR 1.58; 95%
CI 1.20-2.09).
Conclusions: In this observational study, we found that the in-hospital mortality after
pericardiocentesis continues to be high in United States. Shock, renal failure, peripheral
vascular disease, neurologic disorders, metastatic cancer, coagulopathy, electrolyte
abnormalities, and liver disease were significantly associated with an increased risk of
in-hospital mortality.
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Background: Patients with coronary artery disease accompanied by severe left ventric-
ular dilatation (LVD) are at higher risk for heart failure and death. However, their clinical
and angiographic profiles, short- and long-term outcomes after revascularization are
unknown.
Methods: A total of 4,283 patients (median age 60.0 years; 77.4% male) with coronary
artery disease undergoing percutaneous or surgical revascularization in our center from
July, 2003 to September, 2005 were stratified according to end-diastolic dimension
(EDD). Patients with severe LVD (EDD70 mm), mild/moderate LVD (EDD 52.7mm
to 70.0mm in males, EDD 48.3mm to 70.0mm in females), and no LVD (EDD52.7mm
in males, EDD48.3mm in females) was compared for outcome analysis.
Results: Patients with severe LVD had more complex lesions (eg. chronic total
occlusions, multi-vessel disease) with more prior myocardial infarction, valvular impair-
ments and renal dysfunction (all p0.001). Patients successfully discharged were
followed up for a median of 548 (455-669) days. Severe LVD was significantly associated
with increased in-hospital mortality (5.4% vs 1.6% vs 1.0%, p0.001) and composite
ischemia (all-cause mortality, myocardial infarction, stroke and repeat revascularization)
(6.9 % vs 2.5% vs 2.1%, p0.001) compared with mild/moderate LVD and no LVD
groups. By multivariable analysis, severe LVD was a significant independent predictor of
in-hospital (HR 1.858, 95% CI 1.323-2.611, p0.001) and follow-up mortality (HR
1.460, 95% CI 1.037-2.054, p0.030) after revascularization.
Conclusions: Patients with severe LVD have more co-morbidities and complex coronary
lesions. Severe LVD in patients undergoing coronary revascularization was an indepen-
dent predictor of early and late mortality and adverse ischemic outcomes.
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